Besarab A, Caro J F, Ihle B U, Burke J F, Glennon J A, Fischer J A
Nephron. 1981;27(3):127-33. doi: 10.1159/000182038.
Renal osteodystrophy in part due to secondary hyperparathyroidism, is one of the major unresolved problems affecting patients on chronic hemodialysis. In addition, evidence has shown that parathyroid hormone (PTH) is toxic to other organ systems besides bone. The results of a prospective study on the effect of propranolol in reducing PTH levels in chronic renal failure patients on hemodialysis are reported. Propranolol administration reduced PTH levels by over 50-75%. The levels of calcium, phosphorus, alkaline phosphatase and hematocrit were variable, but patients with severe derangements in these measurements also seemed to benefit from propranolol. It should now be determined by larger and longer studies whether these biochemical improvements can be translated into clinical benefits.
部分由继发性甲状旁腺功能亢进引起的肾性骨营养不良，是影响慢性血液透析患者的主要未解决问题之一。此外，有证据表明甲状旁腺激素（PTH）除了对骨骼有毒性外，对其他器官系统也有毒性。本文报道了一项关于普萘洛尔降低慢性肾衰竭血液透析患者PTH水平效果的前瞻性研究结果。服用普萘洛尔使PTH水平降低了50%-75%以上。钙、磷、碱性磷酸酶和血细胞比容水平各不相同，但这些指标严重紊乱的患者似乎也从普萘洛尔中获益。现在应该通过更大规模、更长时间的研究来确定这些生化指标的改善是否能转化为临床益处。
